TrialReader


Impact of Plasma Lipids on β Cell Function and Insulin Sensitivity

NCT05181514 — Not applicable, Completed, 12 participants, Azienda Ospedaliero, Universitaria Pisana

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT05181514
StatusCompleted
PhaseNot applicable
Study typeInterventional; randomized, crossover, masking: single, basic science
Enrollment12 (Actual)
SponsorAzienda Ospedaliero, Universitaria Pisana (Other)
ConditionsHypertriglyceridemia, Glucose Intolerance
Interventions20% Intralipid, Normal Saline (Other)
Datesstart 2019-04-30, primary completion 2021-12-01, completion 2021-12-01, first posted 2022-01-06, last updated 2022-01-06
Locations1 site in Italy

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Hypertriglyceridemia All trials for Glucose Intolerance All trials of 20% Intralipid All trials of Normal Saline

-Summary

The investigators aim to evaluate whether and to what extent glucose tolerance, beta cell function, insulin clearance, and glucose metabolic fluxes change in response to an acute increase in plasma triglycerides during lipid infusion, independently of free fatty acid (FFA) levels, in nondiabetic subjects.

Expand all sections  ·  Collapse all

+Detailed description

Mild hypertriglyceridemia is associated with reduced glucose tolerance and increased risk of type 2 diabetes, independent of obesity, in both cross-sectional and prospective studies. It is unclear whether this association is direct or mediated by circulating lipid substrates of triglycerides (free fatty acids, or FFA) and which are the mechanisms involved.

To comprehensively examine the effects of mild acute hypertriglyceridemia on major glucose homeostatic mechanisms involved in diabetes progression, two dual-labeled oral glucose tolerance tests (OGTT) during 5-hour intravenous infusions of either 20% Intralipid or normal saline will be performed in healthy lean volunteers. Lipid-induced changes in glucose tolerance and insulin metabolism will be evaluated.

+Arms and interventions

ArmTypeInterventionsDescription
Normal SalinePlacebo comparatorOther: Normal SalineParticipants will undergo a dual labeled, 3-h oral glucose tolerance test (OGTT) during i.v. infusion of normal saline
20% IntralipidExperimentalOther: 20% IntralipidParticipants will undergo a dual labeled, 3-h oral glucose tolerance test (OGTT) during i.v. infusion of Intralipid 20%.
  • 20% Intralipid (Other): Participants will receive a 5 h primed (375 mL/m2)-continuous (25 mL h-1 m-2) i.v. infusion of 20% fat emulsion (Intralipid 20%), together with a 5 h primed (28 µmol/kg)-continuous (0.28 µmol min-1 kg-1) infusion of 6,6-\[2H2\]glucose. After 2 h, participants will consume within 5 min an oral glucose drink consisting of 147 mL of 50% dextrose solution (wt/vol) enriched with 1.5 g of \[U-13C\] glucose.
  • Normal Saline (Other): Participants will receive a 5 h primed (375 mL/m2)-continuous (25 mL h-1 m-2) i.v. infusion of normal saline (Sodium Chloride 0.9%), together with a 5 h primed (28 µmol/kg)-continuous (0.28 µmol min-1 kg-1) infusion of 6,6-\[2H2\]glucose. After 2 h, participants will consume within 5 min an oral glucose drink consisting of 147 mL of 50% dextrose solution (wt/vol) enriched with 1.5 g of \[U-13C\] glucose.

+Outcome measures

Primary outcomes

  • Glucose control [At the end of the 5-hour lipid infusion]: Incremental area under the curve (AUC) of plasma glucose in response to the oral glucose tolerance test (OGTT)
  • Insulin secretion [At the end of the 5-hour lipid infusion]: Insulin secretion rate (ISR) estimated from C-peptide deconvolution at fasting and in response to the oral glucose tolerance test (OGTT)
  • Beta cell glucose sensitivity [At the end of the 5-hour lipid infusion]: Beta cell glucose sensitivity calculated by mathematical modeling of insulin secretion rate (ISR) and plasma glucose concentrations during the oral glucose tolerance test (OGTT)
  • Insulin sensitivity [At the end of the 5-hour lipid infusion]: Insulin sensitivity estimated by an OGTT-derived surrogate index (Matsuda index)
  • Insulin clearance [At the end of the 5-hour lipid infusion]: Insulin clearance calculated as the ratio between insulin secretion rate (ISR) and plasma insulin levels
  • Rate of oral glucose appearance (RaO) [At the end of the 5-hour lipid infusion]: The rate of oral glucose appearance (RaO) will be assessed from the time course of the plasma tracer/tracee ratio of 6,6-\[2H2\]glucose and \[U-13C\]glucose
  • Endogenous glucose production (EGP) [At the end of the 5-hour lipid infusion]: The endogenous glucose production (EGP) will be assessed from the time course of the plasma tracer/tracee ratio of 6,6-\[2H2\]glucose and \[U-13C\]glucose

+Eligibility

Sex: All, ages: 18 Years to 65 Years, accepts healthy volunteers

Inclusion Criteria:

* age 18-65 years
* Body mass index (BMI) 18-35 kg/m2
* both women and men

Exclusion Criteria:

* chronic or acute diseases
* any medications
* pregnancy

+Locations (1)

FacilityCityCountryStatus
Azienda Ospedaliero-Universitaria PisanaPisa, PIItaly

+Investigators

My Notes